Pfizer Inc. stock steadies as analysts lift targets and 2026 guidance firms
Published on 09/10/2026 at 11:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer Inc. stock (ISIN US7170811035) closed at USD 27.79 on the NYSE on September 9, 2026, down 2.32% from the prior session after losing 0.66 points on the day per exchange data in USD. According to a note summarized on September 9, 2026, BMO Capital raised its price target on Pfizer from USD 30 to USD 35 while keeping an outperform rating, signaling somewhat greater confidence in the medium-term path for the shares as trading resumes on September 10, 2026, as reported by Ad-hoc-news. For investors, the combination of a modest price setback and firmer analyst targets now frames a more nuanced risk-reward picture.
Guidance for 2026 and revenue outlook
Beyond the daily price swings, the central fundamental anchor for Pfizer stock is the company’s 2026 guidance, which points to expected total revenues between USD 60.5 billion and USD 62.5 billion for the year. According to an overview of the shares published on September 9, 2026, that range implies a relatively tight corridor and reflects a portfolio that is increasingly driven by newer assets rather than legacy COVID revenues, as highlighted by Yahoo Finance. The same analysis notes that Pfizer expects adjusted earnings per share in 2026 in a range of USD 2.80 to USD 3.00, compared with reported adjusted EPS of USD 3.22 in 2025, a decline that is attributed to the dilutive impact of acquisitions such as 3SBio and Metsera, lower COVID product revenues and higher taxes.
The EPS comparison underscores a key tension for shareholders: while the company is guiding to a revenue range that is broadly stable to moderately growing, the bottom line in 2026 is forecast to be about 6.8% to 13.0% below the 2025 level of USD 3.22, based on the USD 2.80-3.00 guidance band. As the same overview points out, the Zacks Consensus Estimate for 2026 EPS has nudged up slightly over the past 60 days from USD 2.97 to USD 2.98, while the consensus for 2027 has climbed from USD 2.86 to USD 2.94, suggesting that analysts expect earnings to stabilize and begin to grow again beyond 2026 according to Yahoo Finance. From a valuation perspective, that same source notes that Pfizer’s shares currently trade at about 9.42 times forward earnings, significantly below an industry multiple of 18.70 and only slightly above the stock’s five-year mean of 9.25.
Analyst ratings and price targets cluster around the current price
Alongside the updated guidance, the analyst landscape around Pfizer stock has become more crowded but also more balanced. As of September 9, 2026, an assessment referenced in a recent blog notes that Pfizer carries eight buy ratings, two outperform ratings, sixteen hold ratings, one underperform rating and one sell rating, with roughly twenty-six analysts publishing a formal price target on the shares according to Tikr. That same analysis describes a mean price target around USD 29, which stands only about 4% above a referenced spot price near USD 28, indicating that, in aggregate, the Street does not currently foresee dramatic upside from present levels.
Other aggregator data paint a similar picture. According to a set of recent filings and analyst summaries compiled by MarketBeat on September 10, 2026, one research analyst currently rates the stock as Strong Buy, four assign a Buy rating, fourteen rate it Hold and two list it as Sell. The same dataset points to an average price target of USD 28.28, again only modestly above recent trading levels around USD 27.79 to USD 28.00. This clustering of targets near the current price suggests that many analysts view the shares as fairly valued, with only selective houses such as BMO Capital seeing more pronounced upside based on their raised USD 35 target mentioned in the September 9, 2026 note summarized by Ad-hoc-news.
Cost savings, pipeline and stock performance in 2026
The earnings outlook and ratings are intertwined with Pfizer’s broader strategic narrative in 2026, which has been shaped by an ambitious cost-saving program and a shifting pipeline mix. A detailed look at the shares notes that Pfizer has pledged USD 9.7 billion in cost savings, a program that underpins expectations for margin resilience even as COVID-related revenues decline, according to Tikr. In the same analysis, the stock is reported to be up about 10% year to date as of early September 2026, with most of that gain occurring after an August 4 EPS beat and a USD 500 million guidance increase that pushed the shares from a USD 24 closing low on June 28, 2026 to around USD 28 by September 8, 2026—a roughly 14% advance within a single quarter.
On the product side, investors are watching whether Pfizer can convert its pipeline investments into durable revenue streams. The 2026 review from Yahoo Finance highlights that Pfizer plans an extensive phase III program for berobenatide, a monthly GLP-1 receptor agonist acquired through its Metsera transaction, positioning the company more directly inside the fast-growing obesity and metabolic disease market. At the same time, that piece notes that the stock has risen about 11.6% so far in 2026 compared with a 14.5% increase for its broader industry, implying that while Pfizer has begun to recover from prior-year pressure, it still trails sector peers on a year-to-date basis.
Valuation, market cap and upcoming events
From a market-capitalization perspective, Pfizer remains a large-cap anchor in global pharmaceuticals. As of early September 2026, a capitalization overview reports that Pfizer’s market cap stands at approximately USD 158.39 billion, with a slightly higher level of USD 162.15 billion noted for September 7, 2026 according to figures compiled by CompaniesMarketCap. Relative to the forward earnings multiple of around 9.42 highlighted by Yahoo Finance and the consensus EPS band, that market cap implies a valuation that is still discounted versus the industry and leaves room for rerating if the company can execute on its cost savings and pipeline plans.
For near-term calendar watchers, an event schedule on September 9, 2026 lists July 24, 2026 as the date of the last dividend declaration, August 4, 2026 as the last earnings release, and September 1, 2026 as the latest dividend payable date for Pfizer. The same schedule points to November 3, 2026 as the estimated date for the next earnings report and notes that Pfizer’s fiscal year ends on December 31, 2026, according to MarketBeat. While the November earnings date remains an estimate rather than a formally confirmed investor-relations calendar entry, it offers investors a provisional anchor for when the next major update on 2026 performance may arrive.
Stock level and recent trading range
In terms of trading levels, Pfizer stock’s September 9, 2026 close of USD 27.79 sits comfortably above its late June low around USD 24 but still below the USD 28 region referenced in several analyst summaries, reflecting partial recovery but not a full retrace of prior declines. During the September 9, 2026 session, the shares moved between roughly USD 27.60 at the intraday low and USD 28.48 at the intraday high, with the closing price near the lower half of the day’s range, indicating that selling interest persisted into the end of trading, as detailed by Ad-hoc-news. That price stands only slightly below the USD 27.86 mid-session quote reported on September 9, 2026 in a NYSE overview, which noted a fair-value price of USD 27.8550, and marks an increase of roughly 11.9% from an earlier low as of June 28, 2026 according to MarketBeat.
Pfizer Inc. stock facts
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Trading venue: NYSE
- Price (as of September 9, 2026): 27.79 USD
- Market capitalization: 158.39 billion USD (as of September 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
- Next earnings date: November 3, 2026 (estimated)
